MET/HGF signaling pathway in ovarian carcinoma

Clinical implications and future direction

Paulette Mhawech-Fauceglia, Michelle Afkhami, Tanja Pejovic

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The HGF/MET signaling pathway is abnormal in numerous cancers including ovarian cancer. MET is expressed in 70% of human cancer and it is overexpressed in 30% of ovarian cases and cancer cell lines. The HGF/MET pathway plays a role in the initiation and progression of ovarian cancer through the most distinctive biologic program known as "invasive growth" which is accomplished through a coordinated activation of cell motility, invasiveness, degradation of extracellular matrix, survival, and proliferation. Because of its ubiquitous role in cancer, the MET axis seems to be an attractive target for cancer therapy. Numerous HGF/MET pathway inhibitor compounds are already in use in clinical trials in various solid tumors. In this paper, we will discuss the HGF/MET pathway in ovarian cancer, its clinical significance, and its potential use as a target therapy in the future.

Original languageEnglish (US)
Article number960327
JournalPathology Research International
Volume2012
DOIs
StatePublished - 2012

Fingerprint

Ovarian Neoplasms
Carcinoma
Neoplasms
Cell Movement
Extracellular Matrix
Direction compound
Clinical Trials
Cell Line
Survival
Therapeutics
Growth

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

MET/HGF signaling pathway in ovarian carcinoma : Clinical implications and future direction. / Mhawech-Fauceglia, Paulette; Afkhami, Michelle; Pejovic, Tanja.

In: Pathology Research International, Vol. 2012, 960327, 2012.

Research output: Contribution to journalArticle

@article{4c260826fe584d999bf1492d416b8c00,
title = "MET/HGF signaling pathway in ovarian carcinoma: Clinical implications and future direction",
abstract = "The HGF/MET signaling pathway is abnormal in numerous cancers including ovarian cancer. MET is expressed in 70{\%} of human cancer and it is overexpressed in 30{\%} of ovarian cases and cancer cell lines. The HGF/MET pathway plays a role in the initiation and progression of ovarian cancer through the most distinctive biologic program known as {"}invasive growth{"} which is accomplished through a coordinated activation of cell motility, invasiveness, degradation of extracellular matrix, survival, and proliferation. Because of its ubiquitous role in cancer, the MET axis seems to be an attractive target for cancer therapy. Numerous HGF/MET pathway inhibitor compounds are already in use in clinical trials in various solid tumors. In this paper, we will discuss the HGF/MET pathway in ovarian cancer, its clinical significance, and its potential use as a target therapy in the future.",
author = "Paulette Mhawech-Fauceglia and Michelle Afkhami and Tanja Pejovic",
year = "2012",
doi = "10.1155/2012/960327",
language = "English (US)",
volume = "2012",
journal = "Pathology Research International",
issn = "2042-003X",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - MET/HGF signaling pathway in ovarian carcinoma

T2 - Clinical implications and future direction

AU - Mhawech-Fauceglia, Paulette

AU - Afkhami, Michelle

AU - Pejovic, Tanja

PY - 2012

Y1 - 2012

N2 - The HGF/MET signaling pathway is abnormal in numerous cancers including ovarian cancer. MET is expressed in 70% of human cancer and it is overexpressed in 30% of ovarian cases and cancer cell lines. The HGF/MET pathway plays a role in the initiation and progression of ovarian cancer through the most distinctive biologic program known as "invasive growth" which is accomplished through a coordinated activation of cell motility, invasiveness, degradation of extracellular matrix, survival, and proliferation. Because of its ubiquitous role in cancer, the MET axis seems to be an attractive target for cancer therapy. Numerous HGF/MET pathway inhibitor compounds are already in use in clinical trials in various solid tumors. In this paper, we will discuss the HGF/MET pathway in ovarian cancer, its clinical significance, and its potential use as a target therapy in the future.

AB - The HGF/MET signaling pathway is abnormal in numerous cancers including ovarian cancer. MET is expressed in 70% of human cancer and it is overexpressed in 30% of ovarian cases and cancer cell lines. The HGF/MET pathway plays a role in the initiation and progression of ovarian cancer through the most distinctive biologic program known as "invasive growth" which is accomplished through a coordinated activation of cell motility, invasiveness, degradation of extracellular matrix, survival, and proliferation. Because of its ubiquitous role in cancer, the MET axis seems to be an attractive target for cancer therapy. Numerous HGF/MET pathway inhibitor compounds are already in use in clinical trials in various solid tumors. In this paper, we will discuss the HGF/MET pathway in ovarian cancer, its clinical significance, and its potential use as a target therapy in the future.

UR - http://www.scopus.com/inward/record.url?scp=84872801636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872801636&partnerID=8YFLogxK

U2 - 10.1155/2012/960327

DO - 10.1155/2012/960327

M3 - Article

VL - 2012

JO - Pathology Research International

JF - Pathology Research International

SN - 2042-003X

M1 - 960327

ER -